Royalty Pharma Acquires Lexiscan® and Cubicin® Royalties for $487 Million
New York, NY (US) – April 4, 2011 — Royalty Pharma announced today that it has acquired the rights to certain royalties payable on sales of Lexiscan® and Cubicin® from an undisclosed seller for a cash payment of $487 million. Lexiscan® (regadenoson) is a market-leading pharmacologic stress agent
